Prof. Todd E. Golde, MD, PhD, from Emory University, Atlanta, GA, discusses the potential of achieving a “goldilocks” response using immunotherapies targeting the amyloid-β plaques found in Alzheimer’s disease. Prof. Golde explains how current immunotherapies can only slow the cognitive decline found in Alzheimer’s disease. More detailed preclinical work may be the key to improving these therapies, particularly for determining the potential for undesirable effects. New omics-level analyses can help to observe issues associated with the removal of amyloid plaques without having to wait to observe negative phenotypes. Improved biomarkers for tracking positive and negative side-effects of immunotherapies are also helping to better understand immunotherapies in transgenic animals and any future human trials. Recorded at the Alzheimer’s Association International Conference (AAIC)® 2023 held in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
